Literature DB >> 9557630

Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants.

S Yerly1, A Rakik, S K De Loes, B Hirschel, D Descamps, F Brun-Vézinet, L Perrin.   

Abstract

Sequences of the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) domain were determined by direct sequencing of HIV-1 RNA in successive plasma samples from eight seroconverting patients infected with virus bearing the T215Y/F amino acid substitution associated with zidovudine (ZDV) resistance. At baseline, additional mutations associated with ZDV resistance were detected. Three patients had the M41L amino acid change, which persisted. Two patients had both the D67N and the K70R amino acid substitutions; reversion to the wild type was seen at both positions in one of these patients and at codon 70 in the other one. Reversion to the wild type at codon 215 was observed in only one of eight patients. Unusual amino acids, such as aspartic acid (D) and cysteine (C), appeared at position 215 in four patients during follow-up. These variants isolated by coculturing were sensitive to ZDV. Overgrowth of these variants suggests that they have better fitness than the original T215Y variant. Intraindividual nucleoside substitutions over time were 10 times more frequent in codons associated with ZDV resistance (41, 67, 70, 215, and 219) than in other codons of the RT domain. The predominance of nonsynonymous substitutions observed over time suggests that most changes reflect adaptation of the RT function. The variance in sequence evolution observed among patients, in particular at codon 215, supports a role for chance in the evolution of the RT domain.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9557630      PMCID: PMC109570          DOI: 10.1128/JVI.72.5.3520-3523.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  Primary infection with zidovudine-resistant human immunodeficiency virus type 1 does not adversely affect outcome at 1 year. Sydney Primary HIV Infection Study Group.

Authors:  A Imrie; A Carr; C Duncombe; R Finlayson; J Vizzard; M Law; J Kaldor; R Penny; D A Cooper
Journal:  J Infect Dis       Date:  1996-07       Impact factor: 5.226

2.  First case of new infection with zidovudine-resistant HIV-1 among prospectively studied intravenous drug users and homosexual men in Amsterdam, The Netherlands.

Authors:  A de Ronde; R Schuurman; J Goudsmit; A van den Hoek; C Boucher
Journal:  AIDS       Date:  1996-02       Impact factor: 4.177

3.  [Prevalence of transmission of zidovudine-resistant viruses in Switzerland. l'Etude suisse de cohorte VIH].

Authors:  S Yerly; A Rakik; S Kinloch-de-Loes; P Erb; P Vernazza; B Hirschel; L Perrin
Journal:  Schweiz Med Wochenschr       Date:  1996-10-26

4.  A controlled trial of zidovudine in primary human immunodeficiency virus infection.

Authors:  S Kinloch-De Loës; B J Hirschel; B Hoen; D A Cooper; B Tindall; A Carr; J H Saurat; N Clumeck; A Lazzarin; L Mathiesen
Journal:  N Engl J Med       Date:  1995-08-17       Impact factor: 91.245

5.  Point mutant frequencies in the pol gene of human immunodeficiency virus type 1 are two- to threefold lower than those of env.

Authors:  M E Quiñones-Mateu; A Holguín; J Dopazo; I Nájera; E Domingo
Journal:  AIDS Res Hum Retroviruses       Date:  1996-08-10       Impact factor: 2.205

6.  Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group.

Authors:  R T D'Aquila; V A Johnson; S L Welles; A J Japour; D R Kuritzkes; V DeGruttola; P S Reichelderfer; R W Coombs; C S Crumpacker; J O Kahn; D D Richman
Journal:  Ann Intern Med       Date:  1995-03-15       Impact factor: 25.391

7.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.

Authors:  D D Ho; A U Neumann; A S Perelson; W Chen; J M Leonard; M Markowitz
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

8.  Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins.

Authors:  W Keulen; C Boucher; B Berkhout
Journal:  Antiviral Res       Date:  1996-06       Impact factor: 5.970

9.  Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group.

Authors:  A J Japour; S Welles; R T D'Aquila; V A Johnson; D D Richman; R W Coombs; P S Reichelderfer; J O Kahn; C S Crumpacker; D R Kuritzkes
Journal:  J Infect Dis       Date:  1995-05       Impact factor: 5.226

10.  Viral dynamics in human immunodeficiency virus type 1 infection.

Authors:  X Wei; S K Ghosh; M E Taylor; V A Johnson; E A Emini; P Deutsch; J D Lifson; S Bonhoeffer; M A Nowak; B H Hahn
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

View more
  28 in total

Review 1.  A fossil record of zidovudine resistance in transmitted isolates of HIV-1.

Authors:  D R Kuritzkes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

2.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

3.  HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance.

Authors:  Soo-Yon Rhee; W Jeffrey Fessel; Andrew R Zolopa; Leo Hurley; Tommy Liu; Jonathan Taylor; Dong Phuong Nguyen; Sally Slome; Daniel Klein; Michael Horberg; Jason Flamm; Stephen Follansbee; Jonathan M Schapiro; Robert W Shafer
Journal:  J Infect Dis       Date:  2005-07-05       Impact factor: 5.226

Review 4.  HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance.

Authors:  Robert W Shafer; Soo-Yon Rhee; Deenan Pillay; Veronica Miller; Paul Sandstrom; Jonathan M Schapiro; Daniel R Kuritzkes; Diane Bennett
Journal:  AIDS       Date:  2007-01-11       Impact factor: 4.177

5.  The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions.

Authors:  Mian-er Cong; Walid Heneine; J Gerardo García-Lerma
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

6.  Case files from Stanford University Medical Center: Drug resistance testing in previously untreated patients with HIV--knowing what to look for and choosing appropriate therapy.

Authors:  Robert W Shafer; Dong Phuong Nguyen; W Jeffrey Fessel
Journal:  MedGenMed       Date:  2006-08-07

7.  The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.

Authors:  Robert W Shafer; Rami Kantor; Matthew J Gonzales
Journal:  AIDS Rev       Date:  2000       Impact factor: 2.500

Review 8.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

Review 9.  Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies.

Authors:  Robert W Shafer; Soo-Yon Rhee; Diane E Bennett
Journal:  Antivir Ther       Date:  2008

10.  Replication and drug resistant mutation of HIV-1 subtype B' (Thailand B) variants isolated from HAART treatment individuals in China.

Authors:  Jianping Sun; Liying Ma; Xiaoling Yu; Yang Huang; Lin Yuan; Yiming Shao
Journal:  Virol J       Date:  2009-11-18       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.